Suppr超能文献

低钙透析液对老年继发性甲状旁腺功能减退血液透析患者的研究

The Study of Low Calcium Dialysate on Elderly Hemodialysis Patients with Secondary Hypoparathyroidism.

作者信息

Lu Jian-Rao, Yi Yang, Xiong Zhong-Xiang, Cheng Xiu-Feng, Hu Jing, Hang Hai-Yan, Cheng Jie, Peng Wen

机构信息

Department of Nephrology, Affiliated Seventh People's Hospital, Shanghai University of TCM, Shanghai, China.

出版信息

Blood Purif. 2016;42(1):3-8. doi: 10.1159/000443470. Epub 2016 Feb 23.

Abstract

OBJECTIVE

The study aimed to study the safety and efficacy of 1.25 mmol/l calcium dialysate on maintenance hemodialysis (MHD) in elderly patients who suffered from secondary hypoparathyroidism.

METHODS

Eighty-two elderly patients (ages ≥65) who had been in MHD with dialysate calcium at 1.5 mmol/l over 6 months and had 2 consecutive serum intact parathyroid hormone (iPTH) measurements at level below 100 pg/ml were selected and randomized into 2 groups: treatment group (41 patients, with dialysate calcium at 1.25 mmol/l) and control group (41 patients, still with dialysate calcium at 1.5 mmol/l). Both groups were studied for the duration of 12 months. The changes of serum iPTH, calcium, phosphorus, calcium and phosphorus product and other indicators as well as related adverse reactions were recorded at the following time points: before the study and 1, 3, 6 and 12 months into the study. In addition, the intimal media thickness (IMT) of carotid artery and abdominal aorta calcification score (AACS) were measured in the 0, 6 and 12 months during the study.

RESULTS

(1) In the treatment group, the levels of serum corrected calcium, phosphorus and calcium-phosphate product began to decline after 1 month and exhibited further decrease 3 months later. Serum iPTH level increased significantly after 1 month into the study and the trend continued. The above markers stabilized after month 6. Compared with pre-study markers, the changes of the above markers were significant after study (p < 0.05). (2) The average IMT and AACS were evidently decreased during the 6 and 12 months of study in the treatment group. There was statistical significance (p < 0.05) when compared with the above indexes of the pre-study and the control group. (3) In the control group, there were no significant differences in above laboratory markers over the 12-month study period. (4) There was no significant difference in the adverse events observed between the 2 groups.

CONCLUSION

Safety of low calcium dialysate (dialysate calcium 1.25 mmol/l) in elderly MHD patients with iPTH <100 pg/ml is good, as well as improving carotid IMT, resistance index and AACS as indexes of vascular calcification in the small study group and warrants further investigation.

摘要

目的

本研究旨在探讨1.25 mmol/l钙透析液对患有继发性甲状旁腺功能减退的老年维持性血液透析(MHD)患者的安全性和有效性。

方法

选取82例年龄≥65岁、接受1.5 mmol/l钙透析液进行MHD治疗6个月以上且连续2次血清完整甲状旁腺激素(iPTH)测量值低于100 pg/ml的老年患者,随机分为2组:治疗组(41例,采用1.25 mmol/l钙透析液)和对照组(41例,仍采用1.5 mmol/l钙透析液)。两组均进行12个月的研究。在以下时间点记录血清iPTH、钙、磷、钙磷乘积等指标的变化以及相关不良反应:研究前、研究开始后1、3、6和12个月。此外,在研究期间的0、6和12个月测量颈动脉内膜中层厚度(IMT)和腹主动脉钙化评分(AACS)。

结果

(1)治疗组血清校正钙、磷和钙磷乘积水平在1个月后开始下降,并在3个月后进一步降低。研究开始1个月后血清iPTH水平显著升高且趋势持续。上述指标在6个月后趋于稳定。与研究前指标相比,研究后上述指标变化具有显著性(p < 0.05)。(2)治疗组在研究的6个月和12个月期间平均IMT和AACS明显降低。与研究前及对照组的上述指标相比具有统计学意义(p < 0.05)。(3)对照组在12个月的研究期间上述实验室指标无显著差异。(4)两组观察到的不良事件无显著差异。

结论

低钙透析液(透析液钙1.25 mmol/l)对iPTH <100 pg/ml的老年MHD患者安全性良好,在小样本研究组中作为血管钙化指标的颈动脉IMT、阻力指数和AACS有所改善,值得进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验